Phase IIstudy of ZD1694 in patients with advanced gastric cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 6, 1996, Pages 628-630

  Meropol, Neal J ^a   Pazdur, Richard ^b   Vincent, Mark ^c   Willson, James K V ^d   Kelsen, David P ^e   Douglass Jr , Harold O ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c LONDON REGIONAL CANCER PROGRAM   (Canada)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Gastric cancer; Thymidylate synthase; Tomudex; ZD1694

Indexed keywords

ANTIEMETIC AGENT; FLUOROURACIL; PACLITAXEL; RALTITREXED; ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC ANTIMETABOLITE; ASPARTATE AMINOTRANSFERASE; ENZYME INHIBITOR; QUINAZOLINE DERIVATIVE; THIOPHENE DERIVATIVE; THYMIDYLATE SYNTHASE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; PHASE 2 CLINICAL TRIAL; STOMACH ADENOCARCINOMA; STOMACH CANCER; THROMBOCYTOPENIA; ADENOCARCINOMA; BLOOD; CANCER STAGING; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; FOLLOW UP; MIDDLE AGED; MUCOSA; MULTICENTER STUDY; NAUSEA; PATHOLOGY; REMISSION; STOMACH TUMOR; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ALANINE TRANSAMINASE; ANTIMETABOLITES, ANTINEOPLASTIC; ASPARTATE AMINOTRANSFERASES; ASTHENIA; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOPENIA; MALE; MIDDLE AGED; MUCOUS MEMBRANE; NAUSEA; NEOPLASM STAGING; QUINAZOLINES; REMISSION INDUCTION; STOMACH NEOPLASMS; THIOPHENES; THROMBOCYTOPENIA; THYMIDYLATE SYNTHASE; VOMITING;

EID: 0029826136     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199612000-00020     Document Type: Article

References (19)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA 1995;45:8-30.
2. Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med 1995;333:32-41.
3. Wilke H, Wils J, Rougier P. et al. Preliminary analysis of a randomized phase III trial of FAMTX versus ELF versus cisplatin/FU in advanced gastric cancer (GC). A trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group and the AIO (Arbeitsge-Meinschaft Internistische Onkologie). Proc Am Soc Clin Oncol 1995;14:500.
4. Cullinan SA, Moertel CG, Wieand HS, et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. J Clin Oncol 1994;12:412-6.
5. Kelsen D. The use of chemotherapy in the treatment of advanced gastric and pancreas cancer. Semin Oncol 1994; 21(suppl 7):58-66.
6. Wils JA, Klein HO, Wagener DJT, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin-a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991;9:827-31.
7. Lenz HJ, Leichman C, Danenberg P, et al. Thymidylate synthase (TS) gene expression predicts response of primary gastric cancer (GC) to 5-fluorouracil (5-FU)-leucovorin (LV)-cisplatin (DDP). Proc Am Soc Clin Oncol 1993;12:199.
8. Johnston PG, Lenz HJ, Danenberg KD, et al. Thymidylate synthase protein and gene expression predicts for response to 5-fluorouracil, leucovorin chemotherapy in patients with colorectal and gastric cancer. Proc Am Soc Clin Oncol 1994;13:196.
9. Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM, Allegra CJ. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989;7:890-9.
10. Johnston PG, Fisher E, Rockette HE, Fisher B, Wolmark N, Allegra CJ. Thymidylate synthase expression is an independent predictor of survival/disease free survival in patients with rectal cancer. Proc Am Soc Clin Oncol 1993;12:202.
11. Peters GL, van der Wilt CL, van Groeningen CJ, Smid K, Meijer S, Pinedo HM. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 1994;12:2035-42.
12. Zalcberg J, Cunningham D, Green M, et al. The final results of a large phase II study of the potent thymidylate synthase (TS) inhibitor Tomudex (ZD1694) in advanced colorectal cancer. Proc Am Soc Clin Oncol 1995;14:204.
13. Smith IE, Spielmann M, Bonneterre J, et al. Tomudex (ZD1694), a new thymidylate synthase inhibitor with antitumor activity in breast cancer. Ann Oncol 1994;5(suppl 5): 132.
14. Burris H, Von Hoff D, Bowen K, et al. A phase II trial of ZD1694, a novel thymidylate synthase inhibitor, in patients with advanced non-small cell lung cancer. Ann Oncol 1994;5(suppl 5):133.
15. World Health Organization. WHO handbook for reporting results of cancer treatment. WHO offset publication #48. Geneva: World Health Organization, 1979.
16. Cancer Therapy Evaluation Program. Common toxicity criteria. In: NCI decision of cancer treatment guidelines for reporting of adverse drug reactions. Bethesda, MD: National Cancer Institute, 1989.
17. Hayward JL, Carbone PP, Hensen JC, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer. Eur J Cancer 1977;13:89-94.
18. Judson I, Clarke S, Ward J, et al. Pharmacokinetics (PK) of ICI D1694 following a 15 minute infusion in patients with advanced cancer. Proc Am Soc Clin Oncol 1992;11:117.
19. Sorensen JM, Jordan E, Grem JL, et al. Phase I trial of D1694: a pure thymidylate synthase inhibitor. Proc Am Soc Clin Oncol 1993;12:158.